Dynamic Inflammatory and Erythrocyte-Derived Biomarkers in Newly Diagnosed Multiple Myeloma: A Longitudinal Analysis of Classical and Novel Indices
Baseline inflammatory and erythrocyte-derived indices, including the novel composite markers MCVL and IIC, have limited prognostic utility in multiple myeloma, and dynamic changes in inflammatory biomarkers during treatment may provide more clinically relevant information regarding disease progression.